The RCAN2–calcineurin–NFAT pathway may potentially serve as a novel molecular target for the development of therapeutic agents against KRAS-mutated CRC and should be further investigated using the previously described mouse models of sporadic colon cancer. This evidence concerns the gene KRAS and colorectal carcinoma.